Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS) on November 29 and set a price target of $55. The company’s shares closed yesterday at $36.44, close to its 52-week low of $32.61.
According to TipRanks.com, Shibutani is a 2-star analyst with an average return of -0.2% and a 36.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Pieris Pharmaceuticals.
Currently, the analyst consensus on Alkermes is a Moderate Buy with an average price target of $47.67, representing a 30.8% upside. In a report issued on November 29, Credit Suisse also maintained a Buy rating on the stock with a $47 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.22 and a one-year low of $32.61. Currently, Alkermes has an average volume of 854.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. It operates through the following geographical segments: U.S., Ireland, Rest of the World, and Other.
